Acucela to Participate in Biotech Showcase™ 2020
SEATTLE--(BUSINESS WIRE)--Dec 23, 2019--
Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo: 4596), announced today its participation in Biotech Showcase™ 2020, being held in San Francisco, CA, from January 13-15, 2020, in parallel with the 38th annual J.P. Morgan Healthcare Conference.
The event will be attended by Jim Niebanck, Chief Commercialization Officer, and Michael Kuran, Business Development and Licensing Advisor, who will introduce Acucela’s game-changing therapeutic and MedTech assets to prospective partners and investors, including the following:
Registered Biotech Showcase™ 2020 attendees may request one-on-one meetings with Acucela through the online partneringONE® system or via direct contact to the principals below.
About Biotech Showcase™
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this important week which sets the tone for the coming year. Now in its twelfth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase™ is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry. For additional information on Biotech Showcase™ 2020, please visit: https://ebdgroup.knect365.com/biotech-showcase/.
About Acucela Inc.
Acucela Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo: 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Acucela’s development pipeline include drug candidates for the treatment of diabetic retinopathy, Stargardt disease, and optogenetics-based gene therapy for the treatment of retinitis pigmentosa. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients. https://www.acucela.com; https://www.kubotaholdings.co.jp/en/
View source version on businesswire.com:https://www.businesswire.com/news/home/20191223005274/en/
CONTACT: Media and Investor Relations Contact:
Chief Financial Officer
Email:firstname.lastname@example.orgBusiness Development & Licensing Contacts:
Chief Commercialization Officer
Business Development and Licensing Advisor
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA WASHINGTON
INDUSTRY KEYWORD: MEDICAL DEVICES DIABETES GENETICS BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL GENERAL HEALTH OPTICAL
SOURCE: Acucela Inc.
Copyright Business Wire 2019.
PUB: 12/23/2019 11:00 AM/DISC: 12/23/2019 11:01 AM